losartan has been researched along with Cognition Disorders in 11 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cotreatment with GW9662, a peroxisome proliferator-activated receptor-γ antagonist, interfered with these protective effects of telmisartan against cognitive function." | 1.38 | Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. ( Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K, 2012) |
| "Telmisartan is a unique angiotensin receptor blocker (ARB) and partial agonist of peroxisome proliferator-activated receptor (PPAR)-gamma." | 1.35 | Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Royea, J | 2 |
| Zhang, L | 1 |
| Tong, XK | 3 |
| Hamel, E | 3 |
| Ongali, B | 2 |
| Nicolakakis, N | 1 |
| Aboulkassim, T | 1 |
| Papadopoulos, P | 1 |
| Rosa-Neto, P | 1 |
| Lecrux, C | 1 |
| Imboden, H | 1 |
| Sun, H | 1 |
| Wu, H | 1 |
| Yu, X | 1 |
| Zhang, G | 1 |
| Zhang, R | 1 |
| Zhan, S | 1 |
| Wang, H | 1 |
| Bu, N | 1 |
| Ma, X | 1 |
| Li, Y | 1 |
| Marchese, NA | 1 |
| Artur de laVillarmois, E | 1 |
| Basmadjian, OM | 1 |
| Perez, MF | 1 |
| Baiardi, G | 1 |
| Bregonzio, C | 1 |
| Mogi, M | 2 |
| Li, JM | 1 |
| Tsukuda, K | 2 |
| Iwanami, J | 2 |
| Min, LJ | 2 |
| Sakata, A | 1 |
| Fujita, T | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 2 |
| Mechaeil, R | 1 |
| Gard, P | 1 |
| Jackson, A | 1 |
| Rusted, J | 1 |
| Shudou, M | 1 |
| Jing, F | 1 |
| Ohshima, K | 1 |
| Tedesco, MA | 1 |
| Ratti, G | 1 |
| Di Salvo, G | 1 |
| Natale, F | 1 |
| Kumagai, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Saruta, T | 1 |
| Jönsson, L | 1 |
| Gerth, W | 1 |
| Fastbom, J | 1 |
3 reviews available for losartan and Cognition Disorders
| Article | Year |
|---|---|
Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Humans; Losartan; Sim | 2016 |
Does the angiotensin II receptor antagonist losartan improve cognitive function?
Topics: Aged; Aged, 80 and over; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2002 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
1 trial available for losartan and Cognition Disorders
| Article | Year |
|---|---|
Cognitive enhancement following acute losartan in normotensive young adults.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cognition; Cognition Dis | 2011 |
7 other studies available for losartan and Cognition Disorders
| Article | Year |
|---|---|
Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Co | 2017 |
Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Angiotensin II Type 1 Receptor Blockers; Animals; | 2014 |
Angiotensin II and its receptor in activated microglia enhanced neuronal loss and cognitive impairment following pilocarpine-induced status epilepticus.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Hippocampus; | 2015 |
Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations.
Topics: Amphetamines; Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Behavior, Animal | 2016 |
Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.
Topics: Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; B | 2008 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Be | 2012 |
The potential economic consequences of cognitive improvement with losartan.
Topics: Adult; Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Cost-Benefit Analysis; Female; | 2002 |